Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 4 endocrinologydiseases
everolimus 1 endocrinologydiseasesdrugs
hyperglycemia 2 endocrinologydiseases
hyperlipidemia 5 endocrinologydiseases
metabolic syndrome 4 endocrinologydiseases
obesity 20 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
everolimus 44826 tacrolimus (TAC)) and mammalian target of rapamycin inhibitors (mTORs) (such as sirolimus (SIR) and everolimus ), have a crucial role. Corticosteroids stimulate gluconeogenesis. CNI stimulates the post-LT occurrence
Select Disease Character Offset Disease Term Instance
diabetes mellitus 3279 NASH will soon become a major indication for LT.INTRODUCTIONParallel to the increasing prevalence of diabetes mellitus type 2 (T2DM) and obesity and a close relationship with insulin resistance (IR) and metabolic risk factors,
diabetes mellitus 32951 centers perform liver biopsies in high risk donors (abnormal liver tests, associated comorbidities, diabetes mellitus , high body mass index, older age, hepatitis B or C infections), others evaluate all potential donors[[11],[54],[58]].
diabetes mellitus 53922 follow-up. The authors noted that post-LT obesity, tacrolimus-based regimen, hyperlipidemia, hypertension, diabetes mellitus , and alcoholic cirrhosis were the primary indications for the LT and, combined with pre-transplant liver
diabetes mellitus 55499 hypercholesterolemia or hypertension. However, in patients with recurrent NAFLD, there was a higher prevalence of diabetes mellitus (100% vs 37.5%). Severe fibrosis (stage 3 or 4) and steatohepatitis at 5 years had a higher incidence
hyperglycemia 44564 are also related to the recipients’ morbidity and mortality[[70],[72]]. For metabolic balance, for hyperglycemia , weight gain, hypertension and hyperlipidemia, immunosuppressant drugs, such as corticosteroids, calcineurin
hyperglycemia 64127 drugs, such as corticosteroids, CNIs and mTORs, have a specific role in metabolic balance and favor hyperglycemia , weight gain, hypertension and hyperlipidemia. These groups of immunosuppressive drugs may, to an extent,
hyperlipidemia 17119 frequently have one or more components of MetS. They are often obese and have T2DM, hypertension and hyperlipidemia . In addition, NASH recipients are older than recipients who have a different CLD[[28]]. According to
hyperlipidemia 44609 morbidity and mortality[[70],[72]]. For metabolic balance, for hyperglycemia, weight gain, hypertension and hyperlipidemia , immunosuppressant drugs, such as corticosteroids, calcineurin inhibitors (CNIs) (cyclosporine (CSA),
hyperlipidemia 45709 three years after LT[[70],[72],[73]]. Of the liver recipients, 10%-64% develop T2DM, 45%-69% experience hyperlipidemia , and approximately 50%-100% develop hypertension after LT[[70]-[72]]. Thus, a significant number of
hyperlipidemia 53892 recipients at the end of the follow-up. The authors noted that post-LT obesity, tacrolimus-based regimen, hyperlipidemia , hypertension, diabetes mellitus, and alcoholic cirrhosis were the primary indications for the LT and,
hyperlipidemia 64172 mTORs, have a specific role in metabolic balance and favor hyperglycemia, weight gain, hypertension and hyperlipidemia . These groups of immunosuppressive drugs may, to an extent, contribute to the formation of CVD by affecting
metabolic syndrome 1878 Current data indicate new trends in the area of chronic liver disease. Due to the increased incidence of metabolic syndrome (MetS) and its components, NASH cirrhosis and hepatocellular carcinoma caused by NASH will soon become
metabolic syndrome 3078 Current data indicate a new trend in the area of chronic liver disease. Due to the increased incidence of metabolic syndrome (MetS) and its components, NASH cirrhosis and hepatocellular carcinoma caused by NASH will soon become
metabolic syndrome 6194 but emerging data suggest that HCC can evolve in non-cirrhotic NAFLD and is strongly associated with metabolic syndrome (MetS)[[8]]. The HCC that is associated with NAFLD/NASH has a distinct phenotype. It is often diagnosed
metabolic syndrome 8528 research for improving health care for this increasing patient population.Figure 1Higher incidence of metabolic syndrome and its complications leads to a higher incidence of nonalcoholic steatohepatitis/nonalcoholic fatty
obesity 3315 indication for LT.INTRODUCTIONParallel to the increasing prevalence of diabetes mellitus type 2 (T2DM) and obesity and a close relationship with insulin resistance (IR) and metabolic risk factors, nonalcoholic fatty
obesity 6568 commonly missed on routine scans for malignancies[[9]]. With the continuous increase in the incidence of obesity , T2DM and MetS in United States (US) and Europe, it is predicted that NAFLD/NASH will become the most
obesity 7467 will become a primary driver of LT in the near future. Furthermore, due to the increasing incidence of obesity , and, consequently MetS, the prevalence of NAFLD in the population will also increase[[1],[2]] As such,
obesity 7907 donors.Moreover, patients who have NASH and are candidates for LT have several comorbidities, such as obesity , T2DM and other MetS components, as well as CVD and CKD. These patients are uniquely challenging LT
obesity 10354 over the next ten or twenty years, the prevalence of NAFLD will increase due to the epidemic rise in obesity , T2DM, arterial hypertension and the prevalence of MetS, as well as people living longer[[10]-[13]].
obesity 16632 poor postoperative and long-term outcomes are age the presence of MetS components (especially T2DM and obesity ), coronary artery disease (CAD) and chronic kidney disease (CKD). Patients who have NASH on the waitlist
obesity 17590 morbidity and mortality in obese patients who underwent surgical procedures. However, in the context of obesity and LT, the results were not consistent. Several studies reported worse outcomes for obese patients,
obesity 18340 obese Class III recipients compared to normal weight recipients. However, patients who had Class II obesity experienced decreased patient and allograft survival[[29]]. Not long ago, Conzen et al[[31]] found that
obesity 18459 decreased patient and allograft survival[[29]]. Not long ago, Conzen et al[[31]] found that morbid obesity had negative effects on long-term outcomes regardless of the short-term results. In other words, there
obesity 19510 addition, the bariatric surgery (BS) methods will become more important in the context of treating obesity for the morbid obesity of NASH patients. There are promising research findings for BS in these patients.
obesity 19533 bariatric surgery (BS) methods will become more important in the context of treating obesity for the morbid obesity of NASH patients. There are promising research findings for BS in these patients. There are studies
obesity 29522 associated comorbidities is highly important; the components of MetS (hypertension, T2DM, dyslipidemia and obesity ) in patients who have low MELD scores can prevent the progression of their comorbid conditions that
obesity 40271 for other causes of ESLD. The predictors of poor outcomes for the recipient and its graft were pre-LT obesity and pre-LT hemodialysis[[28],[65]]. Early postoperative mortality due to infections and CVD events in
obesity 40543 reported in Kennedy et al[[66]]. This study also highlighted that an older age (> 60 years), pre-LT obesity , hypertension and T2DM were associated with lower five-year survival rates after LT. However, the overall
obesity 41706 in the NASH patients. In addition, in line with earlier, small studies, an older age, pre-LT T2DM, obesity and pre-LT hypertension were risk factors for higher mortality rates in the first year after LT[[68]].
obesity 50558 Patatin-like phospholipase in LT recipients is an independent risk factor for post-LT steatosis, as well as obesity and T2DM[[72],[81]].Most research that investigates the prevalence of recurrent NASH in post-LT patients
obesity 53857 extensive fibrosis in 2.25% of recipients at the end of the follow-up. The authors noted that post-LT obesity , tacrolimus-based regimen, hyperlipidemia, hypertension, diabetes mellitus, and alcoholic cirrhosis
obesity 55376 cases were classified as de novo NAFLD. There were no differences in sex, age and the prevalence of obesity , hypercholesterolemia or hypertension. However, in patients with recurrent NAFLD, there was a higher
obesity 56893 challenging. For now, we can attempt to prevent and manage hypertension, dyslipidemia, diabetes and obesity , as well as individualize immunosuppressive therapy in post-LT patients to prevent NAFLD recurrence/development
obesity 60110 Current data indicate a new trend in the area of CLD. Because of the increased incidence of T2DM and obesity , i.e., the growing incidence of MetS, there is a parallel rise in the HCC incidence[[13],[19],[25],[54],[94]].

You must be authorized to submit a review.